Akari Therapeutics (AKTX) Total Non-Current Liabilities (2011 - 2026)
Akari Therapeutics (AKTX) reported Total Non-Current Liabilities of $19.5 million for Q1 2026, down 32.66% on a YoY basis from $28.9 million in Q1 2025, and little changed sequentially from $19.5 million in Q4 2025.
Akari Therapeutics (AKTX) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 11 years of Total Non-Current Liabilities data on file, last reported at $19.5 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 32.66% year-over-year to $19.5 million; the trailing twelve-month figure through Mar 2026 stood at $19.5 million (down 32.66% YoY), and the FY2025 full-year result was $19.5 million, down 30.11% from the prior year.
- Total Non-Current Liabilities was little changed at $19.5 million in Q1 2026, from $19.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $28.9 million in Q1 2025 to a low of $2.6 million in Q3 2024.
- A 5-year average of $14.8 million and a median of $19.5 million in 2026 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities jumped 983.35% in 2025 and slumped 32.66% in 2026, its largest moves.
- Tracing AKTX's Total Non-Current Liabilities over 5 years: stood at $4.2 million in 2022, then grew by 9.07% to $4.6 million in 2023, then surged by 511.73% to $28.0 million in 2024, then tumbled by 30.11% to $19.5 million in 2025, then dropped by 0.21% to $19.5 million in 2026.
- Business Quant data shows AKTX's Total Non-Current Liabilities at $19.5 million in Q1 2026, $19.5 million in Q4 2025, and $22.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 746.94 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 4.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.49 Mn |
| Dec 31, 2025 | 19.53 Mn |
| Sep 30, 2025 | 22.62 Mn |
| Jun 30, 2025 | 25.18 Mn |
| Mar 31, 2025 | 28.95 Mn |
| Dec 31, 2024 | 27.95 Mn |
| Sep 30, 2024 | 2.63 Mn |
| Jun 30, 2024 | 4.98 Mn |
| Mar 31, 2024 | 2.67 Mn |
| Dec 31, 2023 | 4.57 Mn |
| Dec 31, 2022 | 4.19 Mn |
| Dec 31, 2017 | 48,003.00 |
| Dec 31, 2016 | 56,360.00 |
| Mar 31, 2016 | 52,100.00 |
| Dec 31, 2015 | 49,069.00 |
| Sep 30, 2015 | 46,038.00 |
| Jun 30, 2015 | 1.03 Mn |
| Mar 31, 2015 | 812,000.00 |
| Dec 31, 2013 | 787,000.00 |
| Dec 31, 2012 | 630,000.00 |